The deadline for entry to the prestigious PharmaTimes International Clinical Researcher of the Year 2018 is 31 January, so don’t delay, head over to the website today to register your details and get started on the Multiple-Choice Questionnaire. More: International
read moreIt is looking likely that a subgroup of patients with mantle cell lymphoma (MCL) will get routine access to Janssen’s Imbruvica on the NHS. More: NICE recommends Imbruvica for some MCL patients Source: News
read moreShire, the Royal College of Surgeons Ireland (RCSI) and Science Foundation Ireland (SFI), in collaboration with the Irish Haemophilia Society, have initiated a new study that aims to better personalise the care of haemophilia patients. More: Shire and partners launch
read moreCancer Research UK’s subsidiary Cancer Research Technology (CRT) has signed a five-year drug-discovery deal with Celgene to develop and commercialise new anti-cancer treatments. More: Cancer Research Technology links with Celgene Source: News
read moreWith just-arrived competition in mantle cell lymphoma, Johnson & Johnson’s Imbruvica has snagged reimbursement backing in an important new market. More: NICE flip-flops to back J&J's Imbruvica in mantle cell lymphoma Source: fierce
read moreBristol-Myers Squibb could have yet another approval for its Opdivo-plus-Yervoy combo on the way. The FDA has started a priority review on the two-drug combo as a treatment for kidney cancer, based on data released just three months ago. More: FDA puts
read more© 1994 - 2026 B.M. Pharmaceuticals